Previous 10 | Next 10 |
Influenza program Phase 1 clinical trial with CC-42344 on track to begin in the third quarter of 2021 COVID-19 program preclinical development with the novel oral SARS-CoV-2 protease inhibitors is advancing Two IND-enabling studies in the COVID-19 program expected to begin i...
New York, NY – August 03, 2021 – New COVID-19 cases continue to surge throughout the United States, causing municipal governments to spring into action to combat the rising number of the highly infectious Delta variant cases. On Monday, California and New York City announced...
Pinterest (NYSE:PINS) -20% on Q2 earnings release Cassava Sciences (NASDAQ:SAVA) -17% despite presenting 'positive' data on simufilam for Alzheimer's 360 DigiTech (NASDAQ:QFIN) -12%. Annovis Bio (NYSE:ANVS) -11%. Uxin (NASDAQ:UXIN) -11% on Q4 earnings release. Le...
CDI-45205 Shows Efficacy Against Delta Variant Cocrystal announced that its protease inhibitor against the COVID-19 virus, CDI-45205, showed potent in vitro activity against all four major variants. These include the Delta (India or B.1.617.2), Alpha (UK or B.1.1.7), Beta (South African or B.1...
Gainers: Intec Pharma (NASDAQ:NTEC) +61%. LendingClub Corporation (NYSE:LC) +55%. NanoVibronix (NASDAQ:NAOV) +36%. Golden Star Resources (NYSE:GSS) +28%. Dream Finders Homes (NASDAQ:DFH) +17%. E-Home Household Service Holdings (NASDAQ:EJH) +17%. Tempur Sealy International (NYSE:TPX) +16%. Hut...
Gainers: NanoVibronix (NASDAQ:NAOV) +49%, Intec Pharma (NASDAQ:NTEC) +31%, Cocrystal Pharma (NASDAQ:COCP) +17%, Burning Rock Biotech (NASDAQ:BNR) +11%, Genetron (NASDAQ:GTH) +8%. Losers: Annovis Bio (NYSE:ANVS) -48%, Atreca (NASDAQ:BCEL) -35%,...
LendingClub LC +38% on Q2 earnings. Cocrystal Pharma (NASDAQ:COCP) +26% SARS-CoV-2 3CL protease lead CDI-45205 demonstrates Broad-Spectrum activity against the SARS-CoV-2 Delta and Gamma Variants Flora Growth (NASDAQ:FLGC) +20%. Acer Therapeutics (NASDAQ:ACER) +21%. NanoVibroni...
Cocrystal Pharma (NASDAQ:COCP) soars 24.6% premarket after announcing that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed potent in vitro activity against the SARS-CoV-2 Delta (India/B.1.617.2) and Gamma (Brazil/P.1) variants. The company previously reported t...
BOTHELL, Wash., July 29, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed potent in vitro activity against the SARS-CoV-2...
Drug-resistant superbugs have threatened human health for decades. The situation is getting worse because of the shortage of new antibiotics. But what if we changed the way we aim to treat them, and trained our cells to kill these invaders instead of relying on antibiotics to do the dirty work...
News, Short Squeeze, Breakout and More Instantly...
Cocrystal Pharma Inc. Company Name:
COCP Stock Symbol:
NASDAQ Market:
Cocrystal Pharma Inc. Website:
BOTHELL, Wash., July 18, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) today reported favorable safety and tolerability results from the single-ascending dose (SAD) cohorts of the Phase 1 study in healthy volunteers wit...
BOTHELL, Wash., June 20, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc .’s (Nasdaq: COCP) novel, broad-spectrum antiviral CC-42344 inhibits activity in the highly pathogenic avian influenza A (H5N1) PB2 protein recently identified in infected dairy cattle, according to recently ...
Topline single ascending dose (SAD) Phase 1 results of oral CDI-988, the first potential pan-coronavirus-pan-norovirus oral antiviral, expected in the second quarter of 2024 Enrollment completed in Phase 2a influenza A human challenge study of oral CC-42344, with topline results expected ...